期刊文献+

中西医结合治疗类风湿关节炎的疗效观察 被引量:3

Effective observation on treating RA in the integrative medicine
下载PDF
导出
摘要 目的:探讨中西医结合治疗类风湿关节炎的临床疗效。方法:选取我院收治的72例类风湿关节炎患者,随机分为治疗组和对照组各36例,对照组采用单纯西药方案治疗。治疗组在对照组的基础上配合运用我院中药内服、外用等中医特色疗法。结果:两组患者治疗前晨僵时间、关节肿胀数目及压痛数比较,差异无统计学意义(P>0.05),两组患者具有可比性;治疗后两组患者晨僵时间、关节肿胀数目及压痛数比较差异有统计学意义(P<0.05)。两组患者治疗前ESP、CRP、RF比较差异无统计学意义(P>0.05),表明两组患者具有可比性;两组患者治疗后PF比较差异无统计学意义(P>0.05),ESP、CRP比较差异有统计学意义(P<0.05)。两组患者最总有效率比较差异有统计学意义(P=0.0025,P<0.05)。结论:在采用甲氨蝶呤及来氟米特等西医治疗方案基础上配合运用我院中药内服、外用等中医特色疗法,可明显改善患者的临床症状,帮助患者恢复,明显减轻或消除患者痛苦,并提高临床疗效,亦无明显不良反应。 Objective:To explore the clinical effect of the integrative medicine on rheumatoid arthritis.Methods:72patients were randomly divided into the treatment group and control group.The control group was treated with western medicine.The treatment group took TCM medicine more.Results:There were significant differences in morning stiffness time,number of joint swelling and tenderness between two groups after treatment(P<0.05).PF did not show a significant difference between groups after treatment(P>0.05);and ESP,CRP showed significant differences between two groups(P<0.05).The difference in total efficiency between two groups was statistically significant(P=0.0025,P<0.05).Conclusion:The integrative medicine on RA was effective,by improving clinical symptoms,promoting prognosis,and reducing or eliminating pain,with no obvious adverse reaction.
作者 王慧娟 贾龙
出处 《中医临床研究》 2017年第28期14-16,共3页 Clinical Journal Of Chinese Medicine
关键词 类风湿关节炎 中西医结合 临床观察 Rheumatoid arthritis The integrative medicine Clinical observation
  • 相关文献

参考文献5

二级参考文献32

  • 1张洪美,何名江,荆琳.关节镜下自体骨软骨移植治疗伴局灶性软骨缺损的膝骨关节炎[J].中国骨与关节损伤杂志,2013,28(S1):23-24. 被引量:15
  • 2陆方林,王斌.甲氨蝶呤与来氟米特联用治疗类风湿性关节炎临床分析[J].安徽医药,2007,11(8):699-700. 被引量:14
  • 3中华人民共和国卫生部.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002.243.
  • 4王承德.实用中医风湿病学(第2版)[M].北京:人民卫生出版社,2009:504-507.
  • 5SAAG K G, TENG G G, PATKAR N M, et al. American College ofRheumatology 2008 recommendations for the use of non-biologic andbiologic disease-modifying anti-rheumatic drugs in rheumatoidarthritis[J]. Arthritis Rheum,2008,59(6):762-784.
  • 6SMOLEN J S, LENDEWE R, BREEDVELD F C, et al. EULARrecommendations for the management of rheumatoid arthritis withsynthetic and biological disease-modifying anti-rheumaticdrugs[J]. Ann Rheum Dis,2010,69(6):964-975.
  • 7KREMER J, GENOVESE M, CANNON G W, et al. Combination leflunomideand methotrexate (MTX) therapy for patients with activerheumatoid arthritis failing MTX monotherapy : open-labelextension of a randomized, double-blind, placebo controlledtrial[J]. Rheumatol,2004,31(8):1521-1531.
  • 8Gabriel S E,Crowson C S,Kremers H M,et al.Survival in Rheumatoid arthritis:a population-based analysis of trends over 40 years.Arthritis Rheum,2003,48(1):54-58.
  • 9LE LOT X,NICOLAU J,BOUMIER P,et al.Validation of the 2010-ACR/EULAR-classification criteria using newly EULAR-defined erosion for rheumatoid arthritis on the very early arthritis community-based(VEr A)cohort[J].Joint Bone Spine,2015,82(1):38-41.
  • 10VAN RIEL PL.The development of the disease activity score(DAS)and the disease activity score using 28 joint counts(DAS28)[J].Clin Exp Rheumatol,2014,32(5Suppl 85):S65-74.

共引文献478

同被引文献19

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部